A Study Comparing the Pharmacodynamic Properties of Insulin VIAJECT™, Regular Human Insulin, and Insulin Lispro

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01000922
Recruitment Status : Completed
First Posted : October 23, 2009
Last Update Posted : July 29, 2015
Information provided by (Responsible Party):

Brief Summary:
Evaluation of post-prandial blood glucose excursions after a standardized meal and pre meal injections of individual doses of the study insulins.

Condition or disease Intervention/treatment Phase
Diabetes Mellitus Drug: Regular Human Insulin Drug: Lispro Drug: VIAject Drug: VIAject 50% Drug: VIAject/Insulin Glargine Drug: Insulin Glargine/VIAject Phase 2

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 24 participants
Allocation: Non-Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Single Center, Randomized, Open-Label, Crossover Study, Comparing the Pharmacodynamic Properties of Insulin VIAJECT™, Regular Human Insulin, and Insulin Lispro Either in Combination With a Basal Insulin Infusion or With Insulin Glargine Relative to a Standardized Meal in Patients With Type 1 Diabetes
Study Start Date : June 2006
Actual Primary Completion Date : January 2008
Actual Study Completion Date : January 2008

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Experimental: Regular Human Insulin
Single injection
Drug: Regular Human Insulin
Individual dose of RHI administered subcutaneously
Experimental: Lispro
Single injection
Drug: Lispro
Individual dose of lispro administered subcutaneously
Experimental: VIAject
Single injection
Drug: VIAject
Individual dose of VIAject administered subcutaneously
Experimental: VIAject 50%
Single injection
Drug: VIAject 50%
Individual dose of VIAject 50% administered subcutaneously
Experimental: VIAject/Insulin glargine
Single injection
Drug: VIAject/Insulin Glargine
VIAject mixed wiht insulin glargine and administered subcutaneously
Experimental: Insulin Glargine/VIAject
Single injection
Drug: Insulin Glargine/VIAject
Individual dose of VIAject and Insulin Glargine administered seperately and subcutaneously

Primary Outcome Measures :
  1. To compare the maximal post prandial blood glucose concentration and the time to maximal post prandial glucose concentration between the different treatments [ Time Frame: 8 hours ]

Secondary Outcome Measures :
  1. To compare the ppGlucmax for all treatments, the ppTGluc-max, the AUCGluc 0-180 and the AUCGluc 0-360, CGluc-baseline for all treatments. [ Time Frame: 8 hours ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   19 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Established diagnosis of type 1 diabetes for not less than 5 years
  2. HbA1c values of not more than 9%
  3. Age: 19 to 70 years
  4. Sex: Male or Female
  5. Body Mass Index: 18 - 28 kg/m2
  6. Informed consent must be obtained in writing for all volunteers.

Exclusion Criteria:

  1. Type 2 Diabetes mellitus.
  2. History of hypersensitivity to any of the components in the study medication.
  3. History of severe or multiple allergies.
  4. Treatment with any other investigational drug in the last 1 month before study entry.
  5. Treatment with any concomitant medication that in the judgment of the investigator. would interfere with the study results.
  6. Progressive disease likely to prove fatal (e.g. malignancies).
  7. Current drug or alcohol abuse, or a history which in the opinion of the Investigator will impair subject safety or protocol compliance.
  8. Having a significant cardiovascular, respiratory, gastrointestinal, hepatic, renal, neurological, psychiatric and/or hematological disease as evaluated by the investigator.
  9. Blood donation within the last 30 days.
  10. A women who is lactating.
  11. Pregnant women or women intending to become pregnant during the study.
  12. A sexually active woman of childbearing age not actively practicing birth control by using a medically accepted device or therapy.
  13. Positive Serology for HIV, Hepatitis B or Hepatitis C.
  14. Abnormal ECG, safety lab or physical examination results that are deemed clinically significant by the investigator.
  15. A lack of compliance or other reasons which, in the opinion of the investigator, prevent the participation of the subject in the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01000922

United States, California
Profil Institute for Clinical Research, Inc. (PICR)
Chula Vista, California, United States, 91911
Sponsors and Collaborators
Principal Investigator: Marcus Hompesch, MD Profil Institute for Clinical Research, Inc.

Responsible Party: Biodel Identifier: NCT01000922     History of Changes
Other Study ID Numbers: VIAJECT™-010JM
First Posted: October 23, 2009    Key Record Dates
Last Update Posted: July 29, 2015
Last Verified: July 2015

Keywords provided by Biodel:
Mealtime Insulin
Rapid acting insulin
Ultra fast VIAject
prandial insulin

Additional relevant MeSH terms:
Diabetes Mellitus
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Insulin, Globin Zinc
Insulin Glargine
Insulin Lispro
Hypoglycemic Agents
Physiological Effects of Drugs